Mirae Asset Global Investments Co. Ltd. Grows Stock Holdings in Vericel Co. (NASDAQ:VCEL)

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 3.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 26,115 shares of the biotechnology company’s stock after acquiring an additional 767 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Vericel were worth $930,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. DekaBank Deutsche Girozentrale purchased a new position in shares of Vericel during the fourth quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. purchased a new position in Vericel in the 4th quarter worth approximately $197,000. Legato Capital Management LLC raised its holdings in Vericel by 20.6% in the 4th quarter. Legato Capital Management LLC now owns 10,340 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 1,765 shares during the last quarter. Walleye Capital LLC purchased a new position in Vericel in the 3rd quarter worth approximately $2,859,000. Finally, Comerica Bank raised its holdings in Vericel by 61,063.9% in the 3rd quarter. Comerica Bank now owns 208,569 shares of the biotechnology company’s stock worth $6,991,000 after acquiring an additional 208,228 shares during the last quarter.

Analyst Ratings Changes

VCEL has been the subject of a number of recent analyst reports. Truist Financial restated a “buy” rating and issued a $54.00 price objective on shares of Vericel in a report on Tuesday, March 26th. TheStreet upgraded shares of Vericel from a “d+” rating to a “c-” rating in a report on Monday, January 29th. Finally, HC Wainwright boosted their price objective on shares of Vericel from $46.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, March 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.40.

Vericel Trading Up 2.3 %

NASDAQ:VCEL opened at $46.42 on Wednesday. Vericel Co. has a 12 month low of $29.24 and a 12 month high of $53.05. The company has a market cap of $2.25 billion, a PE ratio of -515.78 and a beta of 1.71. The company has a 50 day simple moving average of $47.55 and a two-hundred day simple moving average of $40.63.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, February 29th. The biotechnology company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.08. Vericel had a negative net margin of 1.61% and a negative return on equity of 1.55%. The business had revenue of $65.00 million during the quarter, compared to the consensus estimate of $64.28 million. During the same quarter in the previous year, the firm posted $0.12 EPS. The firm’s revenue was up 23.3% on a year-over-year basis. Research analysts forecast that Vericel Co. will post 0.09 earnings per share for the current year.

Insider Activity

In other news, Director Robert L. Md Zerbe sold 2,300 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $44.22, for a total transaction of $101,706.00. Following the completion of the sale, the director now owns 23,395 shares of the company’s stock, valued at approximately $1,034,526.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Robert L. Md Zerbe sold 2,300 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $44.22, for a total transaction of $101,706.00. Following the completion of the sale, the director now owns 23,395 shares of the company’s stock, valued at approximately $1,034,526.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Sean C. Flynn sold 8,115 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $45.33, for a total transaction of $367,852.95. Following the sale, the senior vice president now directly owns 167 shares of the company’s stock, valued at approximately $7,570.11. The disclosure for this sale can be found here. Insiders sold a total of 56,767 shares of company stock valued at $2,561,506 in the last 90 days. Company insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.